HBM Holdings Limited: Major Jury Verdict in U.S. Patent Litigation Against Amgen
Key Points Investors Must Know
- Jury Verdict in Favor of HBM Holdings: Harbour Antibodies BV, a member of HBM Holdings Group, has won a significant patent infringement lawsuit against Amgen Inc. and its subsidiary Teneobio, Inc. in the United States District Court for the District of Delaware.
- Patent Details: The litigation concerns the protection of the Group’s proprietary antibody discovery platform, invented by Professor Frank Grosveld. These patents (collectively called the “Grosveld Patents”) are central to HBM Holdings’ technology and intellectual property portfolio.
- Trial Outcome: The jury found that Amgen infringed the Grosveld Patent, the infringement was willful, the patent is valid, and Harbour Antibodies is entitled to damages of USD 20.2 million—the full amount requested at trial.
- Potential for Enhanced Damages: Because the infringement was deemed willful, Harbour Antibodies may petition the Court for enhanced damages, potentially up to three times the original award (up to USD 60.6 million).
- Shareholder Impact: This verdict is a significant positive development for HBM Holdings, reinforcing its intellectual property rights and potentially resulting in a material cash award. It may affect the company’s valuation, financial outlook, and share price.
- Ongoing Legal Action: The Group will evaluate further steps regarding the verdict, possible enhanced damages, and additional proceedings related to its wider patent portfolio.
- Future Announcements: HBM Holdings will issue further updates on any material developments in compliance with Hong Kong Listing Rules.
- Caution: Shareholders and potential investors are advised to exercise caution when trading HBM Holdings shares given the ongoing litigation and potential for further material developments.
Detailed Analysis for Investors
The verdict marks a substantial legal and strategic win for HBM Holdings Limited, as the jury found Amgen guilty of not only infringing the Grosveld Patents but doing so willfully. This demonstrates the strength and validity of HBM Holdings’ core technology, underpinning its antibody discovery platform—a major asset for the Group.
The damages awarded—USD 20.2 million—represent the full amount claimed by Harbour Antibodies. If the Court approves enhanced (treble) damages due to the willful nature of the infringement, the total award could reach USD 60.6 million. Such a windfall would significantly bolster HBM Holdings’ financial position, providing substantial cash inflow and potentially funding further R&D and IP enforcement activities.
For shareholders, this litigation outcome is highly price-sensitive. It affirms HBM Holdings’ patent rights and sends a strong signal to the industry regarding the enforceability of its intellectual property. Investors should monitor the situation closely, as further legal developments or announcements could materially impact the company’s share price and valuation.
Board and Leadership
The announcement was made by Dr. Jingsong Wang, Chairman and Executive Director. The Board currently comprises executive directors Dr. Jingsong Wang and Dr. Yiping Rong, alongside four independent non-executive directors: Dr. Robert Irwin Kamen, Dr. Xiaoping Ye, Dr. Albert R. Collinson, and Ms. Weiwei Chen.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Shareholders and investors should exercise caution and conduct their own due diligence before making investment decisions. The outcome of litigation and regulatory events may change, and this article does not guarantee future performance or legal outcomes.
香港投資者專用：HBM Holdings 美國專利訴訟重大勝利詳情
- 陪審團裁決支持HBM Holdings： 集團成員 Harbour Antibodies BV 在美國特拉華州地方法院對Amgen及其子公司Teneobio成功維權，獲勝。
- 專利細節： 訴訟涉及集團抗體發現平台，該技術由創辦人Frank Grosveld教授發明，專利組合稱為「Grosveld專利」。
- 審判結果： 陪審團認定Amgen侵犯Grosveld專利，且屬於故意侵權，專利有效。Harbour Antibodies可獲2,020萬美元賠償，為庭上要求全額。
- 可能加重賠償： 因故意侵權，Harbour Antibodies或可申請加重賠償，最高可達三倍（約6,060萬美元）。
- 對股東影響： 此裁決對HBM Holdings屬重大利好，強化集團知識產權，賠償金亦有機會顯著改善財務狀況，或影響估值及股價。
- 後續法律行動： 集團將評估是否進一步爭取加重賠償及就更廣泛專利組合採取法律行動。
- 將來公告： HBM Holdings將按香港上市規則及時公布重大發展。
- 警示： 股東及投資者應謹慎操作，因訴訟進展或有重大影響。
投資者詳細分析
此裁決不僅確認HBM Holdings抗體技術專利的強大法律效力，也顯示集團維權能力。若判准加重賠償，集團將獲得大額現金，有助未來研發及專利維權。
對股東而言，此消息極具價格敏感性，建議密切留意集團後續公告及法律進展，因其有機會影響股價及估值。
董事會及管理層
公告由董事會主席兼執行董事王勁松博士發布，現任董事會包括執行董事王勁松博士、榮毅平博士及四名獨立非執行董事：Robert Irwin Kamen博士、葉小平博士、Albert R. Collinson博士、陳薇薇女士。
免責聲明
本文只供參考，並不構成投資建議。股東及投資者須自行審慎評估及做出決策。訴訟結果及監管事項或有變化，本文不保證未來表現或法律結果。
